Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of SGN-STNV in Advanced Solid Tumors

NCT04665921 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.

NCT NCT04665921
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04665921 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of SGN-STNV in Advanced Solid Tumors
Lead sponsor
Seagen Inc.
Phase
Phase 1
Overall status
Terminated
Start date
January 18, 2021
Completion date
March 1, 2024
Enrollment
111 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

appendiceal adenocarcinoma, carcinoma, non-small cell lung, colorectal neoplasms, endometrial neoplasms, esophageal neoplasms, exocrine pancreatic adenocarcinoma, gastroesophageal junction carcinoma, her2 negative breast neoplasms, ovarian neoplasms, pseudomyxoma peritonei, stomach neoplasms, uterine cervical neoplasms